Vunakizumab
Vunakizumab is a monoclonal antibody designed for the treatment of various inflammatory conditions. It is a humanized antibody that targets specific cytokines involved in the inflammatory process, thereby modulating the immune response.
Mechanism of Action[edit | edit source]
Vunakizumab works by binding to and neutralizing specific cytokines, which are small proteins that play a crucial role in cell signaling during immune responses. By inhibiting these cytokines, Vunakizumab reduces inflammation and alters the immune system's activity, which can be beneficial in treating autoimmune diseases and other inflammatory conditions.
Clinical Uses[edit | edit source]
Vunakizumab is primarily used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. It has shown efficacy in reducing symptoms and improving quality of life in patients with these conditions.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of Vunakizumab involve its absorption, distribution, metabolism, and excretion. It is typically administered via intravenous infusion, allowing for direct entry into the bloodstream. The drug has a long half-life, which supports less frequent dosing schedules.
Side Effects[edit | edit source]
Common side effects of Vunakizumab include injection site reactions, headache, and upper respiratory tract infections. Serious side effects may include increased risk of infections, hypersensitivity reactions, and potential reactivation of latent infections such as tuberculosis.
Regulatory Status[edit | edit source]
Vunakizumab is approved for use in several countries, including the United States and the European Union, for specific indications. It is subject to ongoing clinical trials to explore additional therapeutic uses and to further assess its safety profile.
Research and Development[edit | edit source]
Ongoing research is focused on expanding the indications for Vunakizumab and improving its formulation to enhance patient compliance and reduce side effects. Studies are also investigating its potential use in other inflammatory and autoimmune conditions.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
